Minocycline — $0 with Membership

Other medications in Infections

• Moxifloxacin
• Ofloxacin
• Oritavancin
• Oseltamivir
• Penicillin VK
• Polymyxin B
• Pyrazinamide
• Raltegravir

About Minocycline

Minocycline is a versatile antibiotic renowned for treating a range of bacterial infections, from severe acne to various respiratory and urinary tract issues. At TheDrugClub, we're committed to making vital medications like minocycline both accessible and affordable. Discover how our members can receive this important prescription for a $0 co-pay, delivered directly to their home.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Minocycline is approved for (FDA label)

ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . ZILXI is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections.

Source: Read the full FDA label on DailyMed. Label effective date: February 9, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Minocycline (FDA label)

Topical foam, 1.5%. Each gram of ZILXI contains 15 mg of minocycline equivalent to 16 mg of minocycline hydrochloride and is supplied as a yellow suspension in a pressurized aluminum aerosol container (can). Foam, 1.5%. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: cbffa96e-2446-43cf-ba5e-38c645302afd. SPL document ID: e5d4b4fa-1951-4fa8-9677-acb97b10c087. Label effective date: February 9, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Minocycline (FDA label)

The most commonly observed adverse reaction (incidence ≥1%) is diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Journey Medical Corporation at 1-855-531-1859 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In three (two Phase 3 and one Phase 2) multicenter, randomized, double-blind, vehicle-controlled trials, adult subjects applied ZILXI or vehicle once daily for 12 weeks. A total of 1,087 subjects were treated with ZILXI and 591 with vehicle. The majority of subjects were White (97%) and female (70%). Approximately 67% were non-Hispanic/Latino. The mean age was 50.0 years and ages ranged from 18 to 86 years. The most common adverse reaction reported by ≥1% of subjects treated with ZILXI and more frequently than in subjects treated with vehicle was diarrhea (1% vs. 0%), respectively.

Source: FDA prescribing information (DailyMed). Set ID: cbffa96e-2446-43cf-ba5e-38c645302afd. SPL document ID: e5d4b4fa-1951-4fa8-9677-acb97b10c087. Label effective date: February 9, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Minocycline (FDA label)

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any other ingredients in ZILXI. This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the ingredients in ZILXI. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: cbffa96e-2446-43cf-ba5e-38c645302afd. SPL document ID: e5d4b4fa-1951-4fa8-9677-acb97b10c087. Label effective date: February 9, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Minocycline (FDA label)

• The propellant in ZILXI is flammable.

Source: FDA prescribing information (DailyMed). Set ID: cbffa96e-2446-43cf-ba5e-38c645302afd. SPL document ID: e5d4b4fa-1951-4fa8-9677-acb97b10c087. Label effective date: February 9, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Minocycline (FDA label)

• Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7.1 ) • Penicillin: avoid coadministration. ( 7.2 ) 7.1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7.2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7.3 Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Source: FDA prescribing information (DailyMed). Set ID: cbffa96e-2446-43cf-ba5e-38c645302afd. SPL document ID: e5d4b4fa-1951-4fa8-9677-acb97b10c087. Label effective date: February 9, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.